STOCK TITAN

Pharvaris NV - PHVS STOCK NEWS

Welcome to our dedicated news page for Pharvaris NV (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pharvaris NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pharvaris NV's position in the market.

Rhea-AI Summary
Pharvaris announces acceptance of two abstracts for ePoster presentation at CIIC Fall 2023 Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
conferences
-
Rhea-AI Summary
Pharvaris to attend Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.68%
Tags
conferences
-
Rhea-AI Summary
Pharvaris announces acceptance of two abstracts for ePoster presentation at German Allergy Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Pharvaris to attend Morgan Stanley healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Pharvaris announces acceptance of three abstracts for presentation at HAEi Regional Conference EMEA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) completed enrollment in Phase 2 CHAPTER-1 prophylactic study with top-line data anticipated by YE2023. The clinical hold on deucrictibant for the on-demand treatment of HAE was lifted, with initiation of global Phase 3 clinical study (RAPIDe-3) anticipated by YE2023. Additionally, a $70 million private placement was completed, resulting in cash and cash equivalents of €179 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
Rhea-AI Summary
Pharvaris shares data from the RAPIDe-1 Phase 2 clinical study of PHVS416 for the treatment of hereditary angioedema attacks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.76%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Pharvaris NV

Nasdaq:PHVS

PHVS Rankings

PHVS Stock Data

1.18B
22.01M
6.05%
83.23%
0.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Leiden

About PHVS

pharvaris is a preclinical stage company focused on bringing an oral bradykinin b2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (hae) and other b2 receptor-mediated indications. the company reunites the core team responsible for the discovery and approval of the hae treatment icatibant. with novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.